By Billy Candra 
A landmark study conducted by researchers at Karolinska Institutet and the Astrid Lindgren Children’s Hospital in Sweden has elucidated how children’s immune systems respond to various types of cancer, with reactions varying significantly based on age. Published in the esteemed journal Cell, these findings mark a critical divergence from adult immune responses to malignancy, offering a profound basis for developing novel, highly tailored treatments specifically for pediatric cancer patients. This discovery introduces a crucial dimension to precision medicine, extending beyond mere tumour genetics to encompass the unique immunological profile of each child.
The Unmet Need in Pediatric Oncology
Childhood cancer, while relatively rare compared to adult cancers, remains a leading cause of disease-related death among children and adolescents globally. Annually, more than 400,000 children and adolescents (0-19 years) are diagnosed with cancer worldwide. In Sweden, approximately 300 children receive a cancer diagnosis each year. Despite significant advancements in treatment over the past few decades, leading to overall survival rates approaching 80% for some common childhood cancers, a substantial proportion of children still face aggressive diseases that are resistant to conventional therapies, or suffer debilitating long-term side effects from intensive treatments such as chemotherapy and radiation. These include secondary cancers, cardiovascular problems, infertility, and neurocognitive impairments, underscoring the urgent need for more effective and less toxic therapeutic strategies.
For decades, pediatric cancer treatment largely mirrored adult protocols, albeit with dose adjustments. However, it has become increasingly clear that childhood cancers are fundamentally different from adult cancers, both genetically and biologically. This recognition has driven a shift towards understanding these unique characteristics, particularly in the realm of immunology. Immunotherapy, a revolutionary class of treatments that harness the body’s own immune system to fight cancer, has transformed the landscape of adult oncology, offering durable responses in previously intractable cancers like melanoma and lung cancer. Yet, its success has largely eluded pediatric patients, with many immunotherapy agents showing limited efficacy in children. This disparity has puzzled oncologists and immunologists alike, highlighting a critical knowledge gap concerning the specific mechanisms of immune activation and regulation in children with cancer.
Professor Petter Brodin, a leading figure in pediatric immunology at the Department of Women’s and Children’s Health, Karolinska Institutet, and a paediatrician at the Astrid Lindgren Children’s Hospital, Karolinska University Hospital, emphasized the gravity of this challenge. "The activation of the immune system is crucial to our ability to fight cancer, but differs profoundly between children and adults," Professor Brodin stated. "If we’re to properly treat childhood cancer, we need to unravel how the child’s immune system is activated and regulated in the presence of cancer, and identify the factors that influence their immune responses." This study represents a monumental step towards filling that void, offering unprecedented insights into the immunological nuances of pediatric malignancies.
Deciphering the Pediatric Immune Landscape: The Study’s Approach
The comprehensive study spanned a six-year period, from 2018 to 2024, involving a cohort of 191 children aged 0 to 18 years. All participants were diagnosed with various types of solid tumours at the Astrid Lindgren Children’s Hospital, a renowned institution at the forefront of pediatric care. The research methodology was meticulous, involving a dual-pronged analysis of both tumour tissue and blood samples from each child. This allowed the researchers to not only identify the specific genetic mutations present within the tumours but also to ascertain which genes were actively expressed or silenced within the immune system. This holistic approach provided a dynamic snapshot of the intricate interplay between the burgeoning tumour and the developing immune system.
By meticulously cataloguing genetic anomalies within tumour cells and concurrently mapping the gene expression profiles of immune cells, the research team aimed to create a detailed immunological fingerprint for each patient. This level of granular analysis is pivotal, moving beyond conventional tumour profiling to integrate the host’s immune response as a central component of disease understanding. Professor Brodin underscored the significance of this broadened perspective, explaining, "Precision medicine in cancer has historically focused almost exclusively on the intrinsic properties of the tumour. By comprehensively characterizing the immune system, we are introducing an entirely new dimension to this field, one that we believe will be instrumental in fundamentally shaping the future of childhood cancer therapy." This expanded definition of precision medicine, encompassing both tumour biology and host immunology, promises a more nuanced and ultimately more effective approach to pediatric oncology.
Fundamental Differences: Children’s Immune System and Cancer
The results of the study unequivocally demonstrated that the immune systems of children and adults respond distinctly to cancer. Furthermore, the research revealed that different types of tumours activate the immune response to varying degrees within the pediatric population itself. These findings challenge the long-held assumption that immune mechanisms are largely similar across age groups, particularly when confronted with malignancy.
A key observation was that children’s tumours are generally characterized by a lower inflammatory signature and fewer genetic mutations compared to their adult counterparts. This translates to a critical immunological implication: "What we can see is that children’s tumours are generally less inflammatory and have fewer mutations, which means that they likely appear less foreign to the immune system and that the immune system therefore doesn’t attack the tumours as forcefully," Professor Brodin elaborated. This reduced "foreignness" means the developing immune system is less likely to mount a robust and sustained attack, allowing the tumour to potentially evade detection and eradication more effectively. The implications are profound, suggesting that the very nature of childhood cancers, coupled with the unique developmental stage of the pediatric immune system, conspires to create an environment less conducive to spontaneous anti-tumour immunity.
However, the study also highlighted significant individual variations within the pediatric cohort. Even within similar tumour types and age groups, the immune responses differed considerably from one child to another. This underscores the paramount importance of precision medicine, reinforcing the principle that treatment regimens must be meticulously adapted to each individual patient’s unique biological and immunological profile. "Our study shows how this can be done in practice," Professor Brodin added, referring to the detailed immune profiling methodology developed by his team. This individualized approach is crucial for optimizing therapeutic outcomes and minimizing unnecessary toxicities in a vulnerable patient population.
Rethinking Immunotherapy for Young Patients
The striking differences observed in pediatric immune responses offer a compelling explanation for the limited success of current immunotherapeutic treatments, particularly checkpoint inhibitors, in children. Checkpoint inhibitors represent a class of biological therapies that work by blocking specific proteins (checkpoints) on immune cells, essentially "releasing the brakes" on the immune system and allowing T cells to more effectively recognize and destroy cancer cells. This strategy has revolutionized the treatment of several adult cancers, yet its efficacy in children has been disappointing across many tumour types.
Professor Brodin explained the underlying immunological reason for this discrepancy: "This [checkpoint inhibition] requires the immune cells to be activated against the tumour. We show that the child’s immune cells are often initially not activated against the tumour, which means that checkpoint inhibitors won’t work." In essence, if the immune system hasn’t already recognized the tumour as a threat and begun to mount an initial response, simply removing the "brakes" will have little effect. It’s akin to trying to accelerate a car that hasn’t even been started.
This pivotal finding suggests that future immunotherapeutic strategies for children must diverge significantly from adult paradigms. Instead of merely disinhibiting an already active immune response, pediatric immunotherapies may need to focus on initiating that response from the ground up. "Children likely need different types of immunotherapies that are more focused on triggering the immune cells to attack the tumour cells from scratch," Professor Brodin posited. This could involve novel approaches such as cancer vaccines designed to prime the immune system against specific pediatric tumour antigens, adoptive cell therapies using genetically engineered T cells that are specifically trained to recognize and eliminate childhood cancer cells, or even combination therapies that first activate the immune system before applying checkpoint blockade. The study’s results are a clear call to action for pharmaceutical companies and academic researchers to invest in the development of these next-generation, child-centric immunotherapies.
Paving the Way for Precision Pediatric Oncology
The study’s implications extend beyond explaining past failures; they illuminate a clear path forward for more effective and precise pediatric oncology. By understanding the specific immunological milieu of a child’s tumour, clinicians could soon be equipped with the knowledge to select the most appropriate therapy for each patient, moving away from a one-size-fits-all approach. This represents a significant leap towards true precision medicine in childhood cancer, integrating not just genomic profiling of the tumour but also deep immunological profiling of the host.
One of the most immediate and clinically actionable findings relates to the tracking of immune responses over time. In a subset of the children involved in the study, researchers were able to longitudinally monitor changes in the population of killer T cells – the specialized immune cells primarily responsible for identifying and destroying cancer cells – throughout the course of treatment. This dynamic monitoring capability offers a powerful new tool for assessing treatment efficacy in real-time.
"This is something that we could make clinical use of today to judge the therapeutic effect and adjust the treatment to every individual patient," Professor Brodin asserted. The ability to observe how killer T cells respond to therapy provides invaluable feedback, allowing clinicians to make informed decisions about continuing, modifying, or escalating treatment strategies. For instance, if killer T cell activity remains low despite initial therapy, it might signal the need for a different immunological approach. Conversely, a robust and sustained increase in killer T cell numbers could indicate a positive response. "We’ll now be testing this on a larger scale as we believe that it can be a useful complement to the genetic analyses of tumours that are already being done in routine care," he added, indicating the team’s commitment to translating these research findings into practical clinical tools.
Real-Time Monitoring and Personalized Treatment Adjustments
The integration of immune response tracking into standard clinical practice holds immense promise. Currently, assessing the efficacy of cancer treatments often relies on imaging techniques (like MRI or CT scans) and tumour markers, which provide information about tumour size and activity but offer limited insight into the underlying biological response, especially at the immune level. By adding immune profiling, particularly the quantification and functional assessment of killer T cells, clinicians would gain a more nuanced and proactive understanding of how a child’s body is fighting the cancer.
This real-time feedback loop could significantly improve patient care by:
- Early Identification of Non-Responders: Allowing for quicker pivot to alternative therapies if the immune system is not adequately engaged.
- Optimization of Immunotherapy: Tailoring the type, dose, and duration of immunotherapy based on the individual’s immune kinetics.
- Minimizing Toxicity: Avoiding prolonged exposure to ineffective treatments, thereby reducing cumulative side effects in children whose developing bodies are particularly vulnerable.
- Informing Combination Therapies: Identifying the optimal sequence or combination of immunotherapies with conventional treatments.
This approach represents a paradigm shift from reactive to proactive treatment management, potentially leading to better outcomes and a higher quality of life for young cancer survivors.
Collaborative Research and Future Horizons
This groundbreaking study was a testament to collaborative scientific endeavor. Professor Petter Brodin led the research in close partnership with Linda Ljungblad, an oncology resident and researcher at Karolinska Institutet, highlighting the crucial synergy between clinical practice and fundamental research. The study’s execution involved intensive collaboration with the paediatric oncology clinic at the Astrid Lindgren Children’s Hospital, Karolinska University Hospital, underscoring the vital role of integrated patient care and research facilities. Such partnerships are indispensable for conducting high-impact translational research that directly benefits patients.
The research was made possible through the generous financial support of several key organizations committed to advancing cancer research and pediatric health. These included the Swedish Cancer Society, a major funder of cancer research in Sweden; the Swedish Childhood Cancer Foundation, dedicated specifically to supporting research into childhood cancers; the Swedish Research Council, a governmental agency funding basic research; the Knut and Alice Wallenberg Foundation, one of Sweden’s largest private research funders; and Karolinska Institutet itself. This broad base of support underscores the recognized importance and potential impact of this research.
Transparency in research is paramount, and it is noted that Professor Petter Brodin, along with two other authors of the study, are co-founders of Cytodelics AB, a company potentially involved in immune profiling technologies. Additionally, Professor Brodin serves on the executive board of Kancera AB and acts as a scientific advisor to several other biotechnology and health tech companies, including Pixelgen Technologies AB, Sention Health AB, Helaina Inc, Scailyte AG, and Oxford Immune Algorithmics. These affiliations are openly disclosed to ensure full transparency regarding potential conflicts of interest, a standard practice in high-impact scientific publications.
Looking ahead, this study opens numerous avenues for future research. Researchers will likely focus on:
- Larger and More Diverse Cohorts: Expanding the study to include more children with a wider range of solid and hematological malignancies to validate and generalize these findings.
- Specific Tumour Subtypes: Delving deeper into the immunological profiles of specific childhood cancers, such as neuroblastoma, medulloblastoma, and sarcomas, which often present unique challenges.
- Novel Immunotherapy Development: Actively pursuing the design and clinical testing of new immunotherapeutic agents tailored to the unique pediatric immune environment.
- Biomarker Discovery: Identifying robust biomarkers that can predict response to therapy or risk of relapse, based on immune profiling.
- Long-Term Outcomes: Monitoring the long-term immunological health and cancer surveillance in children who have received novel immunotherapies.
The findings from Karolinska Institutet represent a pivotal moment in pediatric oncology. By profoundly deepening our understanding of how children’s immune systems interact with cancer, this research not only explains why current immunotherapies often fail in young patients but also provides a clear roadmap for developing the next generation of precision, immune-based treatments. This will undoubtedly lead to more effective, less toxic therapies, offering renewed hope for children battling cancer and their families worldwide.
